Clinical Trial Update: An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma [Phase 2]

View source ↗

Summary

Phase 2 observational study of continuous oral dosing of Abiraterone Acetate in castration-resistant prostate cancer, evaluating androgen and steroid metabolite…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Zytiga) (abiraterone acetate)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Prostate Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-11-01